(August 12, 2016, 1:31 PM EDT) -- WASHINGTON, D.C. — Arguments will be heard Sept. 29 on the centralization of federal lawsuits in which breast cancer patients allege that the chemotherapy drug Taxotere causes permanent hair loss, according to an Aug. 11 hearing order of the Judicial Panel on Multidistrict Litigation (JPMDL) (In Re: Taxotere [Docetaxel] Products Liability Litigation, MDL Docket No. 2740, JPMDL).

The hearing order lists 35 such cases in various federal district courts. In their July 22 motion, two plaintiffs asked the JPMDL to create an MDL in the U.S....